These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12463438)

  • 1. Ankylosing spondylitis--the history of medical therapies.
    Khan MA
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S3-5. PubMed ID: 12463438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dr. Feng Xinghua's experience in treating ankylosing spondylitis.
    Hongxiao L
    J Tradit Chin Med; 2006 Sep; 26(3):207-9. PubMed ID: 17078454
    [No Abstract]   [Full Text] [Related]  

  • 3. Critical appraisal of the guidelines for the management of ankylosing spondylitis: disease-modifying antirheumatic drugs.
    Soriano ER; Clegg DO; Lisse JR
    Am J Med Sci; 2012 May; 343(5):357-9. PubMed ID: 22543537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
    Barthel HR
    Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
    [No Abstract]   [Full Text] [Related]  

  • 5. Don't forget traditional DMARDs.
    Fleischmann R
    Rheumatology (Oxford); 2011 Mar; 50(3):429-30. PubMed ID: 21339283
    [No Abstract]   [Full Text] [Related]  

  • 6. Historical aspects of ankylosing spondylitis.
    Bywaters EG
    Rheumatol Rehabil; 1979 Nov; 18(4):197-203. PubMed ID: 390673
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of etanercept on iritis in patients with ankylosing spondylitis.
    Rosenbaum JT
    Arthritis Rheum; 2004 Nov; 50(11):3736-7. PubMed ID: 15529379
    [No Abstract]   [Full Text] [Related]  

  • 8. Muhammad Asim Khan. Portrait of a rheumatologist as a great artist.
    Boonen A; van der Heijde D; van der Linden S
    J Rheumatol; 2001 Apr; 28(4):843-4. PubMed ID: 11327260
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of ankylosing spondylitis.
    Clegg DO
    J Rheumatol Suppl; 2006 Sep; 78():24-31. PubMed ID: 17042057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM; Bell AL; Cairns AP
    Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained response to anakinra in ankylosing spondylitis.
    Bennett AN; Tan AL; Coates LC; Emery P; Marzo-Ortega H; McGonagle D
    Rheumatology (Oxford); 2008 Feb; 47(2):223-4. PubMed ID: 18073250
    [No Abstract]   [Full Text] [Related]  

  • 13. How to define remission in ankylosing spondylitis?
    Sieper J
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i93-5. PubMed ID: 22460148
    [No Abstract]   [Full Text] [Related]  

  • 14. Pierre Marie. Pioneer investigator in ankylosing spondylitis.
    Benoist M
    Spine (Phila Pa 1976); 1995 Apr; 20(7):849-52. PubMed ID: 7701402
    [No Abstract]   [Full Text] [Related]  

  • 15. Acquired erythrocytosis upon treatment with infliximab for ankylosing spondylitis.
    Antonelli M; Bupathi M; Janakiram M; Hergenroeder P; Khan MA
    J Rheumatol; 2011 Mar; 38(3):581-3. PubMed ID: 21362796
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixed response to tocilizumab for ankylosing spondylitis.
    Henes JC; Horger M; Guenaydin I; Kanz L; Koetter I
    Ann Rheum Dis; 2010 Dec; 69(12):2217-8. PubMed ID: 20525837
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment resistant ankylosing spondylitis with peripheral joint involvement - a case for infliximab?
    Hrycaj P; Lacki JK
    J Rheumatol; 2003 Jan; 30(1):204-6; author reply 206. PubMed ID: 12508417
    [No Abstract]   [Full Text] [Related]  

  • 18. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
    Smith N; Gadsby K; Butt S; Deighton C
    Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
    [No Abstract]   [Full Text] [Related]  

  • 20. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Haug-Rost I; Braun J; Sieper J
    Ann Rheum Dis; 2013 Feb; 72(2):305-6. PubMed ID: 22887847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.